vs
LIFECORE BIOMEDICAL, INC. \DE\（LFCR）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是LIFECORE BIOMEDICAL, INC. \DE\的1.6倍（$50.3M vs $31.1M），READING INTERNATIONAL INC净利率更高（-5.1% vs -32.1%，领先27.0%），LIFECORE BIOMEDICAL, INC. \DE\同比增速更快（-4.5% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $25.0K），过去两年READING INTERNATIONAL INC的营收复合增速更高（5.6% vs -0.1%）
LIFECORE BIOMEDICAL, INC.是一家生物医药企业，专注于研发和生产以透明质酸为主的高品质生物材料，业务覆盖医疗应用产品、制药解决方案、个人护理原料三大核心板块，主要市场遍布北美、欧洲、亚太地区，服务头部医疗器械、制药、美妆品牌客户。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
LFCR vs RDI — 直观对比
营收规模更大
RDI
是对方的1.6倍
$31.1M
营收增速更快
LFCR
高出9.7%
-14.2%
净利率更高
RDI
高出27.0%
-32.1%
自由现金流更多
RDI
多$4.1M
$25.0K
两年增速更快
RDI
近两年复合增速
-0.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.1M | $50.3M |
| 净利润 | $-10.0M | $-2.6M |
| 毛利率 | 25.0% | — |
| 营业利润率 | -9.9% | -1.9% |
| 净利率 | -32.1% | -5.1% |
| 营收同比 | -4.5% | -14.2% |
| 净利润同比 | -52.0% | -14.5% |
| 每股收益（稀释后） | $-0.29 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LFCRRDI
| Q4 25 | — | $50.3M | ||
| Q3 25 | $31.1M | $52.2M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | $35.2M | $40.2M | ||
| Q4 24 | $32.6M | $58.6M | ||
| Q3 24 | $24.7M | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | $35.7M | $45.1M |
净利润LFCRRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $-10.0M | $-4.2M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | $-14.8M | $-4.8M | ||
| Q4 24 | $-6.6M | $-2.2M | ||
| Q3 24 | $-16.2M | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | $15.6M | $-13.2M |
毛利率LFCRRDI
| Q4 25 | — | — | ||
| Q3 25 | 25.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 33.3% | — |
营业利润率LFCRRDI
| Q4 25 | — | -1.9% | ||
| Q3 25 | -9.9% | -0.6% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | -25.7% | -17.2% | ||
| Q4 24 | -6.0% | 2.6% | ||
| Q3 24 | -46.9% | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | -2.5% | -16.7% |
净利率LFCRRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | -32.1% | -8.0% | ||
| Q2 25 | — | -4.4% | ||
| Q1 25 | -42.0% | -11.8% | ||
| Q4 24 | -20.2% | -3.8% | ||
| Q3 24 | -65.7% | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | 43.8% | -29.4% |
每股收益（稀释后）LFCRRDI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.29 | $-0.18 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | $-0.47 | $-0.21 | ||
| Q4 24 | $-0.25 | $-0.11 | ||
| Q3 24 | $-0.53 | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | $0.42 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.9M | $10.5M |
| 总债务越低越好 | $136.0M | $185.1M |
| 股东权益账面价值 | $-10.5M | $-18.2M |
| 总资产 | $235.2M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LFCRRDI
| Q4 25 | — | $10.5M | ||
| Q3 25 | $18.9M | $8.1M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | $5.4M | $5.9M | ||
| Q4 24 | $9.5M | $12.4M | ||
| Q3 24 | — | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $7.5M |
总债务LFCRRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | $136.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $111.3M | $202.7M | ||
| Q3 24 | $106.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $97.1M | — |
股东权益LFCRRDI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $-10.5M | $-12.1M | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | $2.2M | $-8.1M | ||
| Q4 24 | $15.4M | $-4.4M | ||
| Q3 24 | $-3.9M | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | $17.7M | $18.0M |
总资产LFCRRDI
| Q4 25 | — | $434.9M | ||
| Q3 25 | $235.2M | $435.2M | ||
| Q2 25 | — | $438.1M | ||
| Q1 25 | $237.7M | $441.0M | ||
| Q4 24 | $255.4M | $471.0M | ||
| Q3 24 | $246.8M | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | $246.2M | $494.9M |
负债/权益比LFCRRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.8M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $25.0K | $4.1M |
| 自由现金流率自由现金流/营收 | 0.1% | 8.2% |
| 资本支出强度资本支出/营收 | 5.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-16.8M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流LFCRRDI
| Q4 25 | — | $4.3M | ||
| Q3 25 | $1.8M | $295.0K | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | $1.2M | $-7.7M | ||
| Q4 24 | $-6.1M | $8.0M | ||
| Q3 24 | $-613.0K | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | $-1.4M | $-2.8M |
自由现金流LFCRRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | $25.0K | $-246.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | $-4.3M | $-8.0M | ||
| Q4 24 | $-8.6M | $7.0M | ||
| Q3 24 | $-4.0M | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | $-7.8M | $-4.7M |
自由现金流率LFCRRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | 0.1% | -0.5% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | -12.1% | -19.8% | ||
| Q4 24 | -26.3% | 12.0% | ||
| Q3 24 | -16.3% | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | -21.8% | -10.4% |
资本支出强度LFCRRDI
| Q4 25 | — | 0.3% | ||
| Q3 25 | 5.6% | 1.0% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | 15.5% | 0.6% | ||
| Q4 24 | 7.5% | 1.7% | ||
| Q3 24 | 13.9% | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | 17.8% | 4.3% |
现金转化率LFCRRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
